About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
20
2018/02
Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China.
05
2017/12
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties.
27
2017/10
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertise to identify emerging industry leaders and bring global innovation into China.
<<
<
1
2
3
>
>>
Copyright Everest Medicines 2020
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
